ACM
GILD icon

Advent Capital Management’s Gilead Sciences GILD Stock Holding History

Advent Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-300
Closed -$14K – 321
2016
Q3 		$14K Buy
+300
New +$24.4K ﹤0.01% 462
2015
Q4 		– Sell
-40
Closed -$18K – 484
2015
Q3 		$18K Sell
40
-206
-84% -$22.9K ﹤0.01% 470
2015
Q2 		$27K Buy
+246
New +$26.9K ﹤0.01% 469

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Advent Capital Management's GILD Position: Q1 2019 in Review

Advent Capital Management sold out of Gilead Sciences (GILD) in Q1 2019, closing a stake of 78,000 shares — an estimated $4.88M sold.

Advent Capital Management first reported a position in GILD in Q1 2014 and held it in 15 quarters. The position peaked at $6.72M in Q4 2015. 1,492 funds tracked by Wall St. Rank hold GILD as of Q1 2019.

  • Advent Capital Management reported no remaining Gilead Sciences position as of Q1 2019 after selling out during the quarter.
  • Advent Capital Management sold 78,000 Gilead Sciences shares in Q1 2019, an estimated $4.88M.
  • Advent Capital Management first reported a position in Gilead Sciences in Q1 2014 and held it in 15 quarters.
  • Advent Capital Management's Gilead Sciences position peaked at $6.72M in Q4 2015.
  • 1,492 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2019.

Based on Advent Capital Management's 13F filing for Q1 2019, filed 15 May 2019.